Dr. Adam J. Loavenbruck, MD

Dr. Loavenbruck practices at Hennepin County Medical Center in Minneapolis, Minnesota, part of Hennepin County.

Dr. Loavenbruck's NPI, 1932392016, was assigned on August 22, 2007. Dr. Loavenbruck graduated from State University of New York Downstate Medical Center in 2005. Dr. Loavenbruck holds Minnesota license 52599.

Dr. Loavenbruck's primary practice is Hennepin County Medical Center, at 701 Park Avenue, Minneapolis, MN 55415 in Hennepin County. The practice phone is (612) 873-3000.

Dr. Loavenbruck's primary practice is Hennepin County Medical Center in Minneapolis, Minnesota, part of Hennepin County. The medical group on file is Park Nicollet Clinic. Dmand AI also links Dr. Loavenbruck to 2 more group practices and clinics and 1 medical group, each named with a free account. Dr. Loavenbruck's employer is on file too: a hospital.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Loavenbruck practices, 3 sites in all. Vendor and product names are available with a free account.

Neurology is Dr. Loavenbruck's primary specialty in the NPI Registry, under taxonomy code 2084N0400X. Dr. Loavenbruck is licensed in Minnesota.

CMS data shows 220 Medicare services from Dr. Loavenbruck across 8 procedure codes in 2024, for 123 Medicare patients. Medicare paid $14,280 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 123 Medicare patients who saw Dr. Loavenbruck in 2024. The largest group is under 65, with 65 patients. 53% of them have mood disorders, and 52% have depression. 59% are also on Medicaid. Their average risk score is 1.66, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Loavenbruck's median patient age at 48, with 64% women.

In 2024, Dr. Loavenbruck wrote 862 Medicare Part D claims for 133 patients. 95% of them were for generic drugs. CMS names the drug for 694 of them, across 26 drugs with 11 or more claims each, at $53,223 in total drug cost. In 2023, CMS named 498 claims across 19 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 93 out of 100 for Dr. Loavenbruck for performance year 2024, reported as part of a group. Dr. Loavenbruck accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Loavenbruck as offering telehealth.

Dmand AI links 12 papers to Dr. Loavenbruck, published from 2013 to 2025. 2015 was the busiest year, with 2. The most frequent topics are Amyloidosis, Peripheral Nervous System Diseases and Phenotype. Dr. Loavenbruck has published most often in Stat Med. Dr. Loavenbruck's most frequent co-authors are Christopher J. Klein, MD, Wolfgang Singer, MD and Morie A. Gertz, MD.

Dmand AI links Dr. Loavenbruck to 1 clinical trial. Conditions studied include Urinary Bladder, Overactive and Lower Urinary Tract Symptoms.

Dr. Loavenbruck graduated from State University of New York Downstate Medical Center in 2005.